The onset of MTP inhibitors [45] and monoclonal antibodies against ANGPTL3 [16] associated or not with lipoprotein apheresis and PCSK9 inhibitors has opened the possibility of the normalization of LDL-C in homozygous FH; these may even provide one alternative to the latter. This evidence concerns the gene PCSK9 and familial hyperaldosteronism.